SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001562762-22-000453
Filing Date
2022-11-10
Accepted
2022-11-10 07:05:41
Documents
80
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 vaxx-20220930.htm   iXBRL 10-Q 1320332
2 exhibit311.htm EX-31.1 11807
3 exhibit312.htm EX-31.2 11951
4 exhibit321.htm EX-32.1 6170
  Complete submission text file 0001562762-22-000453.txt   6975113

Data Files

Seq Description Document Type Size
5 vaxx-20220930.xsd EX-101.SCH 73988
6 vaxx-20220930_cal.xml EX-101.CAL 82211
7 vaxx-20220930_def.xml EX-101.DEF 511262
8 vaxx-20220930_lab.xml EX-101.LAB 576652
9 vaxx-20220930_pre.xml EX-101.PRE 638605
74 EXTRACTED XBRL INSTANCE DOCUMENT vaxx-20220930_htm.xml XML 806404
Mailing Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201
Business Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201 (254) 244-5739
Vaxxinity, Inc. (Filer) CIK: 0001851657 (see all company filings)

IRS No.: 862083865 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41058 | Film No.: 221374883
SIC: 2834 Pharmaceutical Preparations